Literature DB >> 7907185

Chronic neuroleptic use in manic-depressive illness.

M J Sernyak1, S W Woods.   

Abstract

Although chronic use of neuroleptic medications is generally discouraged in patients with manic-depressive illness, review of the limited data available suggests that such use may be extensive. Evidence for the efficacy, risks, and determinants of chronic neuroleptic use in bipolar patients is also reviewed. Research strategies designed to reduce chronic use are discussed. These include defining the risks of neuroleptic taper after acute use of neuroleptic-lithium combinations, reducing acute neuroleptic use, and randomly assigning lithium-refractory, neuroleptic-maintained patients to comparisons with alternatives such as carbamazepine, valproic acid, or clonazepam.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7907185

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  5 in total

Review 1.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

Review 2.  Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis.

Authors:  Eduard Vieta; Marc Valentí
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

3.  Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists.

Authors:  A Fourrier; I Gasquet; M P Allicar; M Bouhassira; J P Lépine; B Bégaud
Journal:  Br J Clin Pharmacol       Date:  2000-01       Impact factor: 4.335

Review 4.  Candidate Risks Indicators for Bipolar Disorder: Early Intervention Opportunities in High-Risk Youth.

Authors:  Anne Duffy; Steven Jones; Sarah Goodday; Richard Bentall
Journal:  Int J Neuropsychopharmacol       Date:  2015-06-25       Impact factor: 5.176

Review 5.  Acute and long-term treatment of mania.

Authors:  Eduard Vieta; Jose Sanchez-Moreno
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.